Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma

This single arm, open labeled, nora randomized study was aimed to evaluate the toxicity of 3 cycles of MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) with rhG-CSF (5 mu g/kg/day from day 3 to day 14), on 14 patients with previously untreated infiltrating bladder carcinoma. 42 cycles were administered. Chemotherapy toxicity was very low, with 7 % of neutropenia grade 3 or 4.4 % of thrombocytopenia grade 2, no mucositis above grade 2 and no-nadir sepsis. Bone pain related to rhG-CSF occured in 14 % of cycles, 88 % of the cycles were given at full dose without any delay and mean relative dose intensity was 96.4 % (RDI was 100 % for 9 patients), One patient achieved a complete pathological response (cystectomy: 1) and 6 clinical responses with negative transurethral resection. Addition of rhG-CSF to MVAC chemotherapy allows a high dose intensity of MVAC with very low toxicity over 3 cycles. This association should be compared to standard MVAC or intensified regimens to evaluate efficacy, toxicity, and cost effectiveness.